Evidence map›Paper›PMID 38140193›Full record

ArticleVaccines2023

Immunogenicity, Efficacy, and Safety of a Novel Synthetic Microparticle Pre-Erythrocytic Malaria Vaccine in Multiple Host Species.

Thomas J Powell, Jie Tang, Robert Mitchell, Mary E DeRome, Andrea Jacobs, Naveen Palath, Edwin Cardenas, Michelle Yorke, James G Boyd, Stephen A Kaba and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Thomas J PowellArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
Jie TangArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
Robert MitchellDepartment of Microbiology, School of Medicine, New York University, New York, NY 10010, USA.
Mary E DeRomeArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
Andrea JacobsArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
Naveen PalathArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
Edwin CardenasArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
Michelle YorkeArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
James G BoydArtificial Cell Technologies, Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA.
Stephen A KabaMalaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Elizabeth NardinDepartment of Microbiology, School of Medicine, New York University, New York, NY 10010, USA.
Artificial Cell Technologies (United States) · USNew York University · USGreenLight Biosciences (United States) · USMultiple Myeloma Research Foundation · US

Funding

Synthetic nanocapsule malaria vaccinesR43AI091089 · NIAID · ARTIFICIAL CELL TECHNOLOGIES, INC. · PI POWELL, THOMAS J · 2010 to 2011
$600k
NIAID NIH HHS R43 AI091089
6 · The paper itself

Abstract

We previously reported a protective antibody response in mice immunized with synthetic microparticle vaccines made using layer-by-layer fabrication (LbL-MP) and containing the conserved T1BT* epitopes from the

Indexed as

malaria vaccinemicroparticlenon-human primatepeptidesporozoite

Identifiers

PMID38140193
PMCPMC10748200
OpenAlexW4389187666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.